Stenocare

0,314

DKK

-3,68 %

Mindre end 1K følgere

STENO

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-3,68%

-7,1%

-41,85%

-56,76%

-64,19%

-88,73%

-94,33%

-96,91%

-97,7%

Stenocare er aktiv i sundhedsbranchen. Virksomheden har specialiseret sig i udviklingen af medicinsk cannabis. Stenocare er en af de første spillere, der er begyndt at sælge medicinske cannabisolier i Danmark. I fremtiden vil virksomheden også vende sig til andre europæiske markeder med sit produktsortiment. Stenocares har sit hovedkontor med beliggenhed i Randers.

Markedsværdi

12,06 mio. DKK

Aktieomsætning

12,11 t DKK

Omsætning

4,76 mio.

EBIT %

-695,17 %

P/E

-

Udbytteafkast, %

-

Finanskalender

8.5

2025

Delårsrapport Q1'25

21.8

2025

Delårsrapport Q2'25

6.11

2025

Delårsrapport Q3'25

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse22.4.2025, 13.01

Notice to Annual General Meeting in STENOCARE A/S

Pressemeddelelse3.4.2025, 06.00

STENOCARE ASTRUM 10-10 Oil Product Approved for Reimbursement in Germany

Pressemeddelelse31.3.2025, 06.00

STENOCARE Begins Sales of New CBD100 Oil Product in Denmark

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse28.3.2025, 12.25

STENOCARE interview with Proinvestor.com - Annual Report 2024

Selskabsmeddelelse27.3.2025, 07.01

STENOCARE A/S publishes Annual Report 2024

Selskabsmeddelelse27.2.2025, 08.04

STENOCARE: Q4 and Annual Financial Statement Release 2024

Pressemeddelelse14.2.2025, 07.56

STENOCARE - The innovative ASTRUM 10-10 product is now available for Australian patients

Pressemeddelelse29.1.2025, 09.52

STENOCARE A/S Embarks on Strategic Transformation with HQ Relocation and Cultivation Facility Exit

Selskabsmeddelelse22.1.2025, 11.37

STENOCARE A/S: Conditional Rights Issue subscribed to 45.0 percent

Pressemeddelelse20.1.2025, 11.29

STENOCARE - Final deadline for Subscription to New Shares at DKK 0.50 Each

Pressemeddelelse17.1.2025, 07.00

STENOCARE - Final deadline Soon for Subscription to New Shares at DKK 0.50 Each

Pressemeddelelse15.1.2025, 10.57

STENOCARE - The new innovative ASTRUM 10-10 product is now available for German patients

Pressemeddelelse15.1.2025, 07.00

STENOCARE - Deadline Soon for Subscription to New Shares at DKK 0.50 Each

Pressemeddelelse15.1.2025, 07.00

STENOCARE - Deadline for tegning af nye aktier til 0,50 kr. pr. stk. nærmer sig

Pressemeddelelse10.1.2025, 16.03

STENOCARE A/S announces guarantee commitments in ongoing rights issue

Pressemeddelelse9.1.2025, 19.02

STENOCARE - Deadline for tegning af nye aktier til 0,50 kr. pr. stk. nærmer sig

Pressemeddelelse9.1.2025, 18.55

STENOCARE - Deadline soon to subscribe for new shares at DKK 0.50 each

Pressemeddelelse7.1.2025, 10.22

STENOCARE A/S: The subscription period in Stenocare's conditional rights issue begins today for the time limited offer of DKK 0,50 per new share

Pressemeddelelse3.1.2025, 10.21

STENOCARE's Innovative ASTRUM 10-10 Product Now Available for Norwegian Patients

Selskabsmeddelelse18.12.2024, 18.00

STENOCARE A/S: Conditional Rights Issue of up to 20.2 mDKK

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.